EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
The adverse prognosis of most patients with ovarian cancer is related to recurrent disease caused by resistance to chemotherapeutic and targeted therapeutics. Besides their direct activity against tumor cells, monoclonal antibodies and tyrosine kinase inhibitors (TKIs) also influence the antitumoral activity of immune cells, which has important implications for the design of immunotherapies. In this preclinical study, we treated different ovarian cancer cell lines with anti-epidermal growth factor receptor (EGFR) TKIs and co-incubated them with natural killer (NK) cells. We studied treatment-related structural and functional changes on tumor and immune cells in the presence of the anti-EGFR antibody cetuximab and investigated NK-mediated antitumoral activity. We show that long-term exposure of ovarian cancer cells to TKIs leads to reduced responsiveness of intrinsically sensitive cancer cells over time. Inversely, neither long-term treatment with TKIs nor cetuximab could overcome the intrinsic resistance of certain ovarian cancer cells to anti-EGFR agents. Remarkably, tumor cells pretreated with anti-EGFR TKIs showed increased sensitivity towards NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC). In contrast, the cytokine secretion of NK cells was reduced by TKI sensitization. Our data suggest that sensitization of tumor cells by anti-EGFR TKIs differentially modulates interactions with NK cells. These data have important implications for the design of chemo-immuno combination therapies in this tumor entity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“induction of NK-cell-mediated ADCC of ovarian cancer and NSCLC cells”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Mallmann-Gottschalk et al., 2019
Experimental — accuracy not yet measuredIn the citing paper
“Not only EGFR-specific mAbs (Roberti et al., 2011) but also EGFR-targeting TKIs such as erlotinib (in the presence of a tumor-targeting mAb) (Cavazzoni et al., 2012; Mallmann-Gottschalk et al., 2019) promote ADCC by NK cells, which, in the case of TKIs, originates from the upregulation of the mAb target (e.g., EGFR, HER2) by malignant cells (Cavazzoni et al., 2012; Mallmann-Gottschalk et al., 2019”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Mallmann-Gottschalk et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104 · cited 1×
“The MTT colorimetric assay was performed to assess tumor cell viability under anti-EGFR-targeted therapy [49].”
MethodLynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H.-R., Cupissol, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802656 · Cited by 3,726 · cited 1×
“approved for the treatment of metastatic colorectal cancer and advanced head and neck cancer [7,8].”
BackgroundK-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622 · cited 1×
“K-ras mutations and changed EGFR degradation and internalization may provoke resistance to anti-EGFR antibodies [19,20].”
BackgroundA Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172 · cited 1×
“Radical resection followed by platinum-taxane-based chemotherapy recently combined with the anti-VEGF-inhibitor bevacizumab has improved prognosis in the last decade [2].”
BackgroundSelf-citationCetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904 · cited 1×
“approved for the treatment of metastatic colorectal cancer and advanced head and neck cancer [7,8].”
BackgroundCetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
CD107a as a functional marker for the identification of natural killer cell activity
Alter, G., Malenfant, J. M., & Altfeld, M. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.08.008 · Cited by 1,410 · cited 1×
“Since the lysosomal-associated membrane protein-1 (LAMP-1 or CD107a) in NK cells is expressed during degranulation and correlates with NK cell-mediated tumor cell lysis [50], the expression of CD107a on NK cells was used to evaluate natural and antibody-mediated NK cell cytotoxicity.”
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
Mendelsohn, J., & Baselga, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.504 · Cited by 1,255 · cited 1×
“In in vitro and in vivo studies, the chimeric monoclonal antibody cetuximab displays antiproliferative and apoptotic effects and is able to reduce chemotherapy resistance in various human cancer entities including ovarian cancer [5,6].”
BackgroundDendritic Cells Prime Natural Killer Cells by trans-Presenting Interleukin 15
Lucas, M., Schachterle, W., Oberle, K., Aichele, P., & Diefenbach, A. (2007) · Immunity · doi:10.1016/j.immuni.2007.03.006 · Cited by 887
Fehniger, T. A., Shah, M. H., Turner, M. J., VanDeusen, J. B., Whitman, S. P., Cooper, M. A., Suzuki, K., Wechser, M., Goodsaid, F., & Caligiuri, M. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.8.4511 · Cited by 652
Romee, R., Foley, B., Lenvik, T., Wang, Y., Zhang, B., Ankarlo, D., Luo, X., Cooley, S., Verneris, M., Walcheck, B., et al. (2013) · Blood · doi:10.1182/blood-2012-04-425397 · Cited by 552 · cited 1×
“showing that antibody-mediated NK cell stimulation via CD16 enhances the production of IFNγ [46].”
BackgroundMechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
Wheeler, D. L., Huang, S., Kruser, T. J., Nechrebecki, M. M., Armstrong, E. A., Benavente, S., Gondi, V, Hsu, K.-T., & Harari, P. M. (2008) · Oncogene · doi:10.1038/onc.2008.19 · Cited by 550 · cited 1×
“K-ras mutations and changed EGFR degradation and internalization may provoke resistance to anti-EGFR antibodies [19,20].”
BackgroundFAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
Bivona, T. G., Hieronymus, H., Parker, J., Chang, K., Taron, M., Rosell, R., Moonsamy, P., Dahlman, K., Miller, V. A., Costa, C., et al. (2011) · Nature · doi:10.1038/nature09870 · Cited by 396 · cited 1×
“Besides secondary mutations of the EGFR receptor [21] and MET amplification [37], activation of the Fas-/NFkB-pathway by anti-EGFR TKIs may also cause resistance to anti-EGFR agents [38].”
BackgroundDual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR)
Huang, S., Armstrong, E. A., Benavente, S., Chinnaiyan, P., & Harari, P. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0562 · Cited by 366 · cited 1×
“Inversely, gefitinib and erlotinib retained anti-EGFR susceptibility in cetuximab-resistant head and neck and lung cancer cells [34].”
BackgroundGORDON, A. N., FINKLER, N., EDWARDS, R. P., GARCIA, A. A., CROZIER, M., IRWIN, D. H., & BARRETT, E. (2005) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2005.00137.x · Cited by 221
The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer
Bartlett, J., Langdon, S., Simpson, B., Stewart, M., Katsaros, D., Sismondi, P., Love, S., Scott, W., Williams, A., Lessells, A., et al. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.53 · Cited by 211 · cited 2×
“EGFR is overexpressed in most ovarian cancers, which is correlated with poor prognosis [3,4].”
BackgroundImpact of FASL-induced apoptosis in the elimination of tumor cells by NK cells
Screpanti, V., Wallin, R. P. A., Grandien, A., & Ljunggren, H.-G. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2004.07.033 · Cited by 172 · cited 2×
“During antibody-dependent or natural cytotoxicity, NK cells kill tumor cells by releasing perforin/granzymes or by activating apoptotic pathways [26].”
BackgroundLearn, C. A., Hartzell, T. L., Wikstrand, C. J., Archer, G. E., Rich, J. N., Friedman, A. H., Friedman, H. S., Bigner, D. D., & Sampson, J. H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0521 · Cited by 157 · cited 2×
“Besides secondary mutations of the EGFR receptor [21] and MET amplification [37], activation of the Fas-/NFkB-pathway by anti-EGFR TKIs may also cause resistance to anti-EGFR agents [38].”
BackgroundFischer-Colbrie, J., Witt, A., Heinzl, H., Speiser, P., Czerwenka, K. F., Sevelda, P., & Zeillinger, R. (1997) · PubMed · Cited by 156
Posadas, E. M., Liel, M. S., Kwitkowski, V., Minasian, L., Godwin, A. K., Hussain, M. M., Espina, V., Wood, B. J., Steinberg, S. M., & Kohn, E. C. (2007) · Cancer · doi:10.1002/cncr.22545 · Cited by 143
Secord, A. A., Blessing, J. A., Armstrong, D. K., Rodgers, W. H., Miner, Z., Barnes, M. N., Lewandowski, G. S., & Mannel, R. S. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.11.029 · Cited by 132
Janjigian, Y. Y., Azzoli, C. G., Krug, L. M., Pereira, L. K., Rizvi, N. A., Pietanza, M. C., Kris, M. G., Ginsberg, M. S., Pao, W., Miller, V. A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2662 · Cited by 122 · cited 1×
“However, in lung cancer, acquired anti-EGFR TKI resistance could not be overcome by cetuximab [23].”
BackgroundVergote, I. B., Jimeno, A., Joly, F., Katsaros, D., Coens, C., Despierre, E., Marth, C., Hall, M., Steer, C. B., Colombo, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.5669 · Cited by 114 · cited 1×
“However, clinical studies evaluating specific anti-EGFR drugs in unselected ovarian cancer patient populations have failed so far to show a relevant clinical benefit [11,17].”
BackgroundWeickhardt, A. J., Price, T. J., Chong, G., Gebski, V., Pavlakis, N., Johns, T. G., Azad, A., Skrinos, E., Fluck, K., Dobrovic, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.6599 · Cited by 108
Schilder, R. J., Pathak, H. B., Lokshin, A. E., Holloway, R. W., Alvarez, R. D., Aghajanian, C. A., Min, H., Devarajan, K., Ross, E. A., Drescher, C. W., et al. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.12.003 · Cited by 107 · cited 1×
“However, clinical studies evaluating specific anti-EGFR drugs in unselected ovarian cancer patient populations have failed so far to show a relevant clinical benefit [11,17].”
BackgroundPetri, R. M., Hackel, A. M., Hahnel, K., Dumitru, C. A., Bruderek, K., Flohé, S. B., Paschen, A., Lang, S., & Brandau, S. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.06.020 · Cited by 101
Self-citationHuman NK Cells: From Surface Receptors to the Therapy of Leukemias and Solid Tumors
Moretta, L., Pietra, G., Montaldo, E., Vacca, P., Pende, D., Falco, M., Zotto, G. D., Locatelli, F., Moretta, A., & Mingari, M. C. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00087 · Cited by 99
Dai, Q., Ling, Y., Lia, M., Zou, Y.-Y., Kroog, G. S., Iwata, K. K., & Perez-Soler, R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0993 · Cited by 99 · cited 1×
“In preclinical studies, erlotinib showed antiproliferative activity even in platinum-resistant ovarian cancer cell lines [6,12], and gefitinib displayed synergistic effects with cytostatic agents [13].”
BackgroundThe BCR/ABL‐inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity
Salih, J., Hilpert, J., Placke, T., Grünebach, F., Steinle, A., Salih, H. R., & Krusch, M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25233 · Cited by 98 · cited 2×
“However, some multityrosine kinase inhibitors like nilotinib are able to directly impair cytokine-producing NK cells by inducing cell death within the preferentially cytokine-secreting CD56(bright)CD16(-) NK cell subset [45].”
BackgroundKonner, J. A., Schilder, R. J., Derosa, F., Gerst, S. R., Tew, W. P., Sabbatini, P. J., Hensley, M. L., Spriggs, D. R., & Aghajanian, C. A. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.04.018 · Cited by 94
Thomas, H., Jäger, M., Mauel, K., Brandau, S., Lask, S., & Flohé, S. B. (2014) · Mediators of Inflammation · doi:10.1155/2014/143463 · Cited by 75
Self-citationGeller, M. A., Knorr, D. A., Hermanson, D. A., Pribyl, L., Bendzick, L., Mccullar, V., Miller, J. S., & Kaufman, D. S. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.05.022 · Cited by 73 · cited 1×
“In addition, patient-derived xenograft models could be used to assess the therapeutic effects of NK cells and targeted substances on human samples in an in vivo environment [47,48].”
BackgroundEGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells
Kim, H., Kim, S.-H., Kim, M.-J., Kim, S.-J., Park, S.-J., Chung, J.-S., Bae, J.-H., & Kang, C.-D. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31821b724a · Cited by 63 · cited 1×
“In these cells, sensitization even caused enhanced natural NK cell-mediated tumor cell lysis in the absence of a specific antibody [41,42].”
BackgroundBlank, S. V., Christos, P. J., Curtin, J. P., Goldman, N. A., Runowicz, C. D., Sparano, J. A., Liebes, L., Chen, H. X., & Muggia, F. M. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.08.008 · Cited by 56
Chambers, S. K., Clouser, M. C., Baker, A. F., Roe, D. J., Cui, H., BREWER, M. A., Hatch, K. D., Gordon, M. S., Janicek, M. F., Isaacs, J. D., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0974 · Cited by 56
Watanabe, S., Hayashi, H., Haratani, K., Shimizu, S., Tanizaki, J., Sakai, K., Kawakami, H., Yonesaka, K., Tsurutani, J., Togashi, Y., et al. (2019) · Cancer Science · doi:10.1111/cas.13860 · Cited by 56 · cited 1×
“However, in this study an increase of the MHC I expression on treated cells was reported [43].”
BackgroundTrastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics
Wilken, J. A., Webster, K. T., & Maihle, N. J. (2010) · Journal of Ovarian Research · doi:10.1186/1757-2215-3-7 · Cited by 54 · cited 1×
“Other studies have shown that long-term treatment of ovarian cancer cells with the anti-Her2-antibody trastuzumab potentiated the responsiveness to gefitinib and cetuximab sig ificantly, although the cells were functionally resistant to trastuzumab [36].”
BackgroundImplications of EGFR inhibition in ovarian cancer cell proliferation
Phelps, S. L. B., Schorge, J. O., Peyton, M. J., Shigematsu, H., Xiang, L.-L., Miller, D. S., & Lea, J. S. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.02.030 · Cited by 44
Cavazzoni, A., Alfieri, R. R., Cretella, D., Saccani, F., Ampollini, L., Galetti, M., Quaini, F., Graiani, G., Madeddu, D., Mozzoni, P., et al. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-91 · Cited by 44 · cited 1×
“Compared to unsensitized controls, sensitized cells in this study showed enhanced ADCC after adding cetuximab [40].”
BackgroundChen, S., Li, X., Chen, R., Yin, M., & Zheng, Q. (2016) · Oncology Letters · doi:10.3892/ol.2016.4835 · Cited by 39 · cited 1×
“In addition, patient-derived xenograft models could be used to assess the therapeutic effects of NK cells and targeted substances on human samples in an in vivo environment [47,48].”
BackgroundBjörkelund, H., Gedda, L., Malmqvist, M., & Andersson, K. (2012) · Molecular and Clinical Oncology · doi:10.3892/mco.2012.37 · Cited by 35 · cited 1×
“However, selected published data suggest that anti-EGFR TKIs may reduce the degree of internalization of the EGF receptor [39] which may lead to altered receptor expression.”
BackgroundBae, J., Kim, S.-J., Kim, M.-J., Oh, S.-O., Chung, J., Kim, S.-H., & Kang, C. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2011.02109.x · Cited by 34 · cited 1×
“In these cells, sensitization even caused enhanced natural NK cell-mediated tumor cell lysis in the absence of a specific antibody [41,42].”
BackgroundWang, M., Zhao, J., Zhang, L. M., Li, H., Yu, J.-P., Ren, X.-B., & Wang, C.-L. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1291-2 · Cited by 30 · cited 1×
“These results are in line with studies on lung cancer cells with acquired resistance to erlotinib which could be overcome by the addition of cetuximab only partially [33].”
ResultGottschalk, N., Kimmig, R., Lang, S., Singh, M., & Brandau, S. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms130912000 · Cited by 29 · cited 8×
“In addition, our previous studies revealed that most ovarian cancer cell lines show functional resistance to the anti-EGFR antibody cetuximab which could not be resolved by the simultaneous addition of the corresponding anti-EGFR TKIs [24].”
BackgroundMethodSelf-citationPupo, E., Ducano, N., Lupo, B., Vigna, E., Avanzato, D., Perera, T. P. S., Trusolino, L., Lanzetti, L., & Comoglio, P. M. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3107 · Cited by 29 · cited 1×
“Besides secondary mutations of the EGFR receptor [21] and MET amplification [37], activation of the Fas-/NFkB-pathway by anti-EGFR TKIs may also cause resistance to anti-EGFR agents [38].”
BackgroundHorn, L., Gettinger, S. N., Camidge, D. R., Smit, E. F., Janjigian, Y. Y., Miller, V. A., Pao, W. J., Freiwald, M., Fan, J., Wang, B., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.08.014 · Cited by 21
Smith, J. A., Gaikwad, A., Jiang, Y. L., Wolf, J. K., Brown, J., Ramondetta, L. M., & Stewart, C. F. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0572-y · Cited by 13 · cited 1×
“In preclinical studies, erlotinib showed antiproliferative activity even in platinum-resistant ovarian cancer cell lines [6,12], and gefitinib displayed synergistic effects with cytostatic agents [13].”
BackgroundErlotinib enhances the CIK cell-killing sensitivity of lung adenocarcinoma A549 cells
Mei, J., Liu, G. J., Zhang, X. J., Zhao, J., & Feng, R. (2015) · Genetics and Molecular Research · doi:10.4238/2015.april.10.18 · Cited by 7 · cited 1×
“Of note, similar data have been reported in the literature where erlotinib induced downregulation of MICA in lung cancer cells and still enhanced sensitivity to killer cells [44].”
BackgroundGottschalk, N., Lang, S., Kimmig, R., Singh, M., & Brandau, S. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-451 · Cited by 6 · cited 1×
“Our own previous studies have revealed that ovarian cancer cells show predominant resistance to NK cell-mediated natural cytotoxicity [24,32].”
BackgroundSelf-citation
Cited by
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 160
Baci, D., Bosi, A., Gallazzi, M., Rizzi, M., Noonan, D. M., Poggi, A. D., Bruno, A., & Mortara, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093125 · Cited by 147
“Abbreviations HB-EGF Heparin-Binding EGF-like Growth Factor HGSOC High-Grade Serous Ovarian Cancer HSCs Hematopoietic Stem Cells Hu-mAb Humanized monoclonal antibodies IFNγ Interferon γ iNOS Inducible Nitric Oxide Synthase iPSC Induced Pluripotent Stem Cell LPS Lipo Poly Saccharide MCP-1/CCL2 Monocyte Chemoattractant…”
BackgroundInfluentialAn immunogenomic signature for molecular classification in hepatocellular carcinoma
Zhuang, W., Sun, H., Zhang, S., Zhou, Y., Weng, W., Wu, B., Ye, T., Huang, W., Lin, Z., Shi, L., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.06.024 · Cited by 71
“NK cells have strong anti-tumor activity and release perforin/granzymes or activate apoptosis pathways to kill tumor cells.(9) In addition, NK cells can also secrete cytokines, such as interferon (IFN)-g and tumor necrosis factor (TNF)-a, to inhibit tumor cell proliferation, tumor angiogenesis, and multistage cancerat…”
BackgroundBaysal, H., Pauw, I. D., Zaryouh, H., Peeters, M., Vermorken, J. B., Lardon, F., Waele, J. D., & Wouters, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.737311 · Cited by 67
Metadata
- Authors
- Mallmann-Gottschalk, N., Sax, Y., Kimmig, R., Lang, S., & Brandau, S.
- Affiliations
- Department of Gynecology and Obstetrics, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany
- University of Duisburg-Essen (DE)
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-09-22
- Volume
- 20
- Issue
- 19
- Pages
- 4693
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6801374
- OpenAlex
- W2973955555
- Cited by
- 31
- References
- 50
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 5 · 2023: 3 · 2022: 4 · 2021: 8 · 2020: 7
- FWCI
- 1.90
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Deutsche Forschungsgemeinschaft
- Universität Duisburg-Essen
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- ovarian cancer, EGFR tyrosine kinase inhibitors, cetuximab, natural killer cells, NK cell cytotoxicity, antibody-dependent cellular cytotoxicity, anti-EGFR antibody resistance, tumor sensitization, immunotherapy
- MeSH terms
- Antineoplastic Agents, Immunological, Antibody-Dependent Cell Cytotoxicity, Cell Survival, Cytotoxicity, Immunologic, Female, Humans, Killer Cells, Natural, Ligands, Ovarian Neoplasms, Biomarkers, Cytokines, Cell Line, Tumor, Protein Kinase Inhibitors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.